Information  X 
Enter a valid email address

Evgen Pharma PLC (EVG)

  Print      Mail a friend

Monday 03 December, 2018

Evgen Pharma PLC

Notification of Half Year Results

RNS Number : 1205J
Evgen Pharma PLC
03 December 2018
 

For immediate release

 

3 December 2018

 

 

Evgen Pharma plc

("Evgen" or "the Company")

 

Notification of Half Year Results

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its interim results for the six months ended 30 September 2018 on Wednesday 12 December 2018.

Enquiries:

Evgen Pharma plc

Dr Stephen Franklin, CEO

Richard Moulson, CFO

www.evgen.com

c/o +44 (0) 20 7466 5000

 



Buchanan

Mark Court, Sophie Wills, Tilly Abraham

+44 (0) 20 7466 5000

 



Northland Capital Partners Limited

Matthew Johnson, Gerry Beaney (Corporate Finance)

Rob Rees (Corporate Broking)

 

+44 (0) 20 3861 6625

WG Partners LLP

Nigel Barnes, Claes Spång

+44 (0) 20 3705 9330

Notes for editors:

About Evgen Pharma plc

Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/ 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORBMBFTMBTJBFP

a d v e r t i s e m e n t